



Picato® (ingenol mebutate) – Product discontinuation

- On October 27, 2020, [LEO Pharma announced](#) the permanent discontinuation in the manufacture of [Picato \(ingenol mebutate\) gel](#).
 - Picato is being discontinued due to business reasons and is not due to any safety, efficacy or quality reasons.
 - The phase-out is expected to be completed by year-end 2020.
- Picato is approved for the topical treatment of actinic keratosis.
- Patients can continue to use their existing Picato until their supply runs out, but they will need to eventually switch over to an alternative.
- Patients currently using Picato should consult with their healthcare professional for guidance on other available treatments for actinic keratosis.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.